Program
tibulizumab
Also written as “LY3090106”, “Tibulizumab Dose A” and “Tibulizumab Dose B”.
Its studies are mostly in Hidradenitis Suppurativa · Scleroderma, Systemic · Sjogren's Syndrome · Arthritis, Rheumatoid, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 30 open or running | phase 1since Aug 15, 2013 | Aug 15, 2013 | none ahead |
| Zura Bio | 22 open or running | phase 2since Feb 7, 2025 | Feb 7, 2025 | May 2027phase 2 · NCT06843239 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2013First study: phase 1 study in Arthritis, RheumatoidNew to Eli LillyEli Lilly · NCT01925157 · 43 enrolled · Bulgaria, Moldova, Republic of, Poland and more
- Nov 24, 2015Phase 1 study in Sjogren's SyndromeEli Lilly · NCT02614716 · 32 enrolled · United States, Bulgaria, Georgia and more
- Nov 8, 2018Phase 1 study in HealthyEli Lilly · NCT03736772 · 30 enrolled · United States
- Feb 7, 2025Zura Bio's first study: phase 2 study in Scleroderma, SystemicNew to Zura BioZura Bio · NCT06843239 · 80 enrolled · United States, Argentina, Chile and more
- May 19, 2025Phase 2 study in Hidradenitis SuppurativaZura Bio · NCT06993610 · 247 enrolled · United States, Canada, Germany and more
Ahead
- May 2027Primary completion: phase 2 study in Scleroderma, SystemicZura Bio · NCT06843239
TargetBeta
“Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor”ChEMBL 37, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06993610Hidradenitis Suppurativa · United States, Canada, Germany and more | 2 | Active, not recruiting | Zura Bio | Sep 18, 2026 | 247 |
| NCT06843239Scleroderma, Systemic · United States, Argentina, Chile and more | 2 | Active, not recruiting | Zura Bio | May 2027 | 80 |
| NCT03736772Healthy · United States | 1 | Completed | Eli Lilly | Mar 13, 2019 | 30 |
| NCT02614716Sjogren's Syndrome · United States, Bulgaria, Georgia and more | 1 | Completed | Eli Lilly | Sep 5, 2018 | 32 |
| NCT01925157Arthritis, Rheumatoid · Bulgaria, Moldova, Republic of, Poland and more | 1 | Completed | Eli Lilly | Jan 2015 | 43 |
How it is read
Names in the registry
- “LY3090106”, 2 entries
- “Tibulizumab Dose A”, 1 entry
- “Tibulizumab Dose B”, 1 entry
- “Tibulizumab”, 1 entry
- “LY3090106 - SQ”, 1 entry
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 1 study
- Scleroderma, Systemic, 1 study
- Sjogren's Syndrome, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.